14M Genomics Ltd. Appoints Alan Schafer As Chief Executive Officer
Cambridge, UK - 14M Genomics, a developer of cancer clinical diagnostic and treatment decision tools, announced today the appointment of Alan Schafer, PhD to the post of Chief Executive Officer.
Dr. Schafer brings extensive experience in research, in big pharma and biotechnology management, as well as in building new businesses. Alan previously served as CEO of Population Genetics Technologies where he led the development and commercialisation strategy for next generation sequencing based diagnostic products to inform clinical decision-making in infectious disease.
Prior to this, Alan served as the Wellcome Trust’s Director of Science Funding and was previously Global Vice-President of Technology Development at GlaxoSmithKline. Alan was a co-founder of Hexagen, a functional genomics company that was acquired by Incyte where he subsequently served as Vice President of Genetics. He has also provided advisory and consultancy services to investment and biotechnology firms.
“We are delighted to have Alan lead our development and commercialisation of clinical genomics diagnostic and treatment decision support services in cancer,” said Andrew Sandham, Executive Chairman of 14M Genomics.
Commenting on his appointment as CEO, Alan Schafer added: “I am devoted to excellence in research and its application to improve the diagnosis and treatment of cancer patients. I am delighted to be joining 14M Genomics, and I look forward to working together with the oncology community, academic institutes and pharmaceutical partners to provide clinical benefit and improve the lives of cancer patients.”
About 14M Genomics
14M Genomics aims to become a European leader in the provision of clinical genomics services and clinical decision support tools, which will inform the diagnosis, prognosis and treatment of cancer. The company employs state-of-the-art sequencing and analytical tools, coupled with an in-depth understanding of cancer biology, to reveal associations between tumour genomics and the clinical path of the individual patient. 14MG aims to work together with the oncology community, academic institutions and pharmaceutical partners to improve the lives of cancer patients.
Help employers find you! Check out all the jobs and post your resume.
Dr. Schafer brings extensive experience in research, in big pharma and biotechnology management, as well as in building new businesses. Alan previously served as CEO of Population Genetics Technologies where he led the development and commercialisation strategy for next generation sequencing based diagnostic products to inform clinical decision-making in infectious disease.
Prior to this, Alan served as the Wellcome Trust’s Director of Science Funding and was previously Global Vice-President of Technology Development at GlaxoSmithKline. Alan was a co-founder of Hexagen, a functional genomics company that was acquired by Incyte where he subsequently served as Vice President of Genetics. He has also provided advisory and consultancy services to investment and biotechnology firms.
“We are delighted to have Alan lead our development and commercialisation of clinical genomics diagnostic and treatment decision support services in cancer,” said Andrew Sandham, Executive Chairman of 14M Genomics.
Commenting on his appointment as CEO, Alan Schafer added: “I am devoted to excellence in research and its application to improve the diagnosis and treatment of cancer patients. I am delighted to be joining 14M Genomics, and I look forward to working together with the oncology community, academic institutes and pharmaceutical partners to provide clinical benefit and improve the lives of cancer patients.”
About 14M Genomics
14M Genomics aims to become a European leader in the provision of clinical genomics services and clinical decision support tools, which will inform the diagnosis, prognosis and treatment of cancer. The company employs state-of-the-art sequencing and analytical tools, coupled with an in-depth understanding of cancer biology, to reveal associations between tumour genomics and the clinical path of the individual patient. 14MG aims to work together with the oncology community, academic institutions and pharmaceutical partners to improve the lives of cancer patients.
Help employers find you! Check out all the jobs and post your resume.